Therapeutically, PARP inhibitors selectively inhibit single-strand break repair processes in homologous recombination deficient cancers, thereby promoting the accumulation of excessive double-strand break that ultimately culminates in selective tumor cell death through the principle of synthetic lethality (Kim et al., 2021). This evidence concerns the gene PARP1 and cancer.